DanDrit Biotech USA, Inc. (Filer) CIK: 0001527728
v2.4.1.9
Document and Entity Information
3 Months Ended
Mar. 31, 2015
May 11, 2015
Document and Entity Information [Abstract]    
Entity Registrant Name DanDrit Biotech USA, Inc.  
Entity Central Index Key 0001527728  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Type 10-Q  
Document Period End Date Mar. 31, 2015  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2015  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock Shares Outstanding   9,533,290dei_EntityCommonStockSharesOutstanding
v2.4.1.9
Consolidated Balance Sheets (USD $)
Mar. 31, 2015
Dec. 31, 2014
CURRENT ASSETS:    
Cash $ 3,434,935us-gaap_CashAndCashEquivalentsAtCarryingValue $ 3,008,831us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash held in escrow    2,029,502us-gaap_EscrowDeposit
Other Receivables 41,120us-gaap_AccountsAndOtherReceivablesNetCurrent 8,016us-gaap_AccountsAndOtherReceivablesNetCurrent
Total Current Assets 3,476,055us-gaap_AssetsCurrent 5,046,349us-gaap_AssetsCurrent
PROPERTY AND EQUIPMENT, Net accumulated Depreciation      
OTHER ASSETS    
Definite Life Intangible Assets 161,062us-gaap_FiniteLivedIntangibleAssetsNet 186,414us-gaap_FiniteLivedIntangibleAssetsNet
Deposits 6,326us-gaap_DepositsAssetsNoncurrent 7,146us-gaap_DepositsAssetsNoncurrent
Total Other Assets 167,388us-gaap_AssetsNoncurrent 193,560us-gaap_AssetsNoncurrent
TOTAL ASSETS 3,643,443us-gaap_Assets 5,239,909us-gaap_Assets
CURRENT LIABILITIES:    
Notes Payable - Related Party 99,305us-gaap_NotesPayableRelatedPartiesClassifiedCurrent 99,951us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
Accounts Payable 622,187us-gaap_AccountsPayableCurrent 711,449us-gaap_AccountsPayableCurrent
Accounts Payable - Related Party 200,857us-gaap_AccountsPayableRelatedPartiesCurrent 212,438us-gaap_AccountsPayableRelatedPartiesCurrent
Accrued Expenses 49,619us-gaap_AccruedLiabilitiesCurrent 733,826us-gaap_AccruedLiabilitiesCurrent
Total Current Liabilities 971,968us-gaap_LiabilitiesCurrent 1,757,664us-gaap_LiabilitiesCurrent
Total Liabilities 971,968us-gaap_Liabilities 1,757,664us-gaap_Liabilities
STOCKHOLDER'S EQUITY:    
Preferred stock, $.0001 par value; 10,000,000 shares authorized; none issued and outstanding      
Common stock, par value $0.0001, 100,000,000 shares authorized, 9,533,290, and 9,533,290 issued and outstanding at March 31, 2015 and December 31, 2014, respectively 953us-gaap_CommonStockValue 953us-gaap_CommonStockValue
Additional paid-in capital 25,098,050us-gaap_AdditionalPaidInCapital 25,098,050us-gaap_AdditionalPaidInCapital
Accumulated Deficit (23,145,352)us-gaap_RetainedEarningsAccumulatedDeficit (21,892,007)us-gaap_RetainedEarningsAccumulatedDeficit
Other Comprehensive Income, net 717,824us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax 275,249us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax
Total Stockholder's Equity 2,671,475us-gaap_StockholdersEquity 3,482,245us-gaap_StockholdersEquity
TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY $ 3,643,443us-gaap_LiabilitiesAndStockholdersEquity $ 5,239,909us-gaap_LiabilitiesAndStockholdersEquity
v2.4.1.9
Consolidated Balance Sheets (Parenthetical) (USD $)
Mar. 31, 2015
Dec. 31, 2014
Statement of Financial Position [Abstract]    
Preferred stock, Par value $ 0.0001us-gaap_PreferredStockParOrStatedValuePerShare $ 0.0001us-gaap_PreferredStockParOrStatedValuePerShare
Preferred stock, Shares authorized 10,000,000us-gaap_PreferredStockSharesAuthorized 10,000,000us-gaap_PreferredStockSharesAuthorized
Preferred stock, Shares issued      
Preferred stock, shares outstanding      
Common stock, Par value $ 0.0001us-gaap_CommonStockParOrStatedValuePerShare $ 0.0001us-gaap_CommonStockParOrStatedValuePerShare
Common stock, Shares authorized 100,000,000us-gaap_CommonStockSharesAuthorized 100,000,000us-gaap_CommonStockSharesAuthorized
Common stock, Shares issued 9,533,290us-gaap_CommonStockSharesIssued 9,533,290us-gaap_CommonStockSharesIssued
Common stock, Shares outstanding 9,533,290us-gaap_CommonStockSharesOutstanding 9,533,290us-gaap_CommonStockSharesOutstanding
v2.4.1.9
Consolidated Statement of Operations (Unaudited) (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Statement of Operations [Abstract]    
Revenues      
Cost of Goods Sold 44,622us-gaap_CostOfGoodsSold 17,739us-gaap_CostOfGoodsSold
Gross (Loss) (44,622)us-gaap_GrossProfit (17,739)us-gaap_GrossProfit
Operating Expenses    
General and Administrative Expenses 372,996us-gaap_GeneralAndAdministrativeExpense 326,428us-gaap_GeneralAndAdministrativeExpense
Research and development expense 151,813us-gaap_ResearchAndDevelopmentExpense   
Depreciation and Amortization 4,055us-gaap_DepreciationDepletionAndAmortization 6,794us-gaap_DepreciationDepletionAndAmortization
Consulting Expenses 291,998pmhs_ConsultingExpenses 61,145pmhs_ConsultingExpenses
Total Operating Expense 820,862us-gaap_OperatingExpenses 394,367us-gaap_OperatingExpenses
(LOSS) FROM OPERATIONS (865,484)us-gaap_OperatingIncomeLoss (412,106)us-gaap_OperatingIncomeLoss
Other Income (Expense)    
Interest (expense) (1,540)us-gaap_InterestExpense (13,999)us-gaap_InterestExpense
(Loss) on Currency Transactions (392,474)us-gaap_ForeignCurrencyTransactionGainLossRealized   
Interest and Other Income 6,153us-gaap_InterestIncomeOther 51us-gaap_InterestIncomeOther
Total Other Income (Expense) (387,861)us-gaap_NonoperatingIncomeExpense (13,948)us-gaap_NonoperatingIncomeExpense
(Loss) Before Income Taxes (1,253,345)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest (426,054)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income Tax Expense (Benefit)      
NET (LOSS) $ (1,253,345)us-gaap_NetIncomeLoss $ (426,054)us-gaap_NetIncomeLoss
BASIC AND DILUTED LOSS PER SHARE $ (0.13)us-gaap_EarningsPerShareBasicAndDiluted $ (0.06)us-gaap_EarningsPerShareBasicAndDiluted
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED 9,553,290us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 6,880,278us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted
v2.4.1.9
Statements of Other Comprehensive Loss (Unaudited) (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
STATEMENTS OF OTHER COMPREHENSIVE LOSS [Abstract]    
Net Loss $ (1,253,345)us-gaap_NetIncomeLoss $ (426,054)us-gaap_NetIncomeLoss
Currency Translation, Net of Taxes 442,575us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax (3,354)us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
Other Comprehensive Loss $ (810,770)us-gaap_ComprehensiveIncomeNetOfTax $ (429,408)us-gaap_ComprehensiveIncomeNetOfTax
v2.4.1.9
Consolidated Statement of Cash Flows (Unaudited) (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Statement of Cash Flows [Abstract]    
NET (LOSS) $ (1,253,345)us-gaap_NetIncomeLoss $ (426,054)us-gaap_NetIncomeLoss
ADJUSTMENT TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:    
Depreciation and Amortization 25,352us-gaap_DepreciationAndAmortization 6,794us-gaap_DepreciationAndAmortization
Accrued Interest on Notes Payable - Related Party 1,540us-gaap_IncreaseDecreaseInInterestPayableNet  
CHANGES IN ASSETS AND LIABILITIES:    
(Increase) Decrease in Other Receivables (33,104)us-gaap_IncreaseDecreaseInOtherReceivables (44,256)us-gaap_IncreaseDecreaseInOtherReceivables
(Increase) Decrease in Prepaid Expenses/Deposits 820pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits 8,047pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits
Increase (Decrease) in Accounts Payable (89,262)us-gaap_IncreaseDecreaseInAccountsPayable 19,674us-gaap_IncreaseDecreaseInAccountsPayable
Increase (Decrease) in Accounts Payable - Related Party (11,581)us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties  
Increase (Decrease) in Accrued Expenses (684,207)us-gaap_IncreaseDecreaseInAccruedLiabilities (1,951)us-gaap_IncreaseDecreaseInAccruedLiabilities
Total Adjustments (790,442)us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities (11,692)us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
NET CASH USED IN OPERATING ACTIVITIES (2,043,787)us-gaap_NetCashProvidedByUsedInOperatingActivities (437,746)us-gaap_NetCashProvidedByUsedInOperatingActivities
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of Equipment    (41,498)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Net (Increase) Decrease in Cash Held in Escrow 2,029,502pmhs_NetIncreaseDecreaseInCashHeldInEscrow (346,501)pmhs_NetIncreaseDecreaseInCashHeldInEscrow
Purchase of Intangible Assets    (7,907)us-gaap_PaymentsToAcquireIntangibleAssets
NET CASH USED BY INVESTING ACTIVITIES 2,029,502us-gaap_NetCashProvidedByUsedInInvestingActivities (395,906)us-gaap_NetCashProvidedByUsedInInvestingActivities
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from Notes Payable - Related Party    865,976us-gaap_ProceedsFromNotesPayable
NET CASH PROVIDED BY (USED BY) FINANCING ACTIVITIES    865,976us-gaap_NetCashProvidedByUsedInFinancingActivities
Gain (Loss) on Currency Translation 440,389us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents 3,354us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents
NET INCREASE (DECREASE) IN CASH 426,104us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 35,678us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
CASH, BEGINNING OF PERIOD 3,008,831us-gaap_CashAndCashEquivalentsAtCarryingValue 18,794us-gaap_CashAndCashEquivalentsAtCarryingValue
CASH, END OF PERIOD 3,434,935us-gaap_CashAndCashEquivalentsAtCarryingValue 54,472us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash paid during the periods for:    
Interest      
Income Taxes      
v2.4.1.9
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2015
Summary of Significant Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2015 and 2014 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2014 audited financial statements. The results of operations for the periods ended March 31, 2015 and 2014 are not necessarily indicative of the operating results for the full year.

 

Business and Basis of Presentation — DanDrit Biotech USA, Inc. (“DanDrit USA”, the “Company”, “we”, “us”, “our”) (formerly Putnam Hills Corp) was originally incorporated in the state of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business.

 

DanDrit BioTech A/S, a Danish Corporation was incorporated on April 1, 2001 (“DanDrit Denmark”) a 96,92% owned subsidiary of the Company. The Company engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the human treatment of cancer using the dendritic cell technology.

 

Reverse Acquisition — On February 12, 2014, pursuant to the Share Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA completed the acquisition of 100% of the issued and outstanding capital stock of DanDrit Denmark (the “Share Exchange”) and as a result became DanDrit Denmark’s parent company (the “Parent”). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the “Common Stock”) of Parent outstanding. Parent and an existing shareholder agreed to cancel 4,400,000 shares of its Common Stock and issued 1,440,000 shares of Common Stock for legal and consulting services related to the Share Exchange and a future public offering. At the time of the Share Exchange each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of Parent’s Common Stock, for a total of 6,000,000 shares, resulting in 8,040,000 shares of the Parent’s Common Stock outstanding immediately following the Share Exchange, including 185,053 shares of Common Stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the DanDrit Denmark shareholders who have not consented to the Share Exchange (the “Non-Consenting Shareholders”), and deemed issued and outstanding for accounting purposes.

 

Consolidation — For the three months ended March 31, 2015 and 2014, the consolidated financial statements include the accounts and operations of the DanDrit Denmark, and the accounts and operations of DanDrit USA. All material inter-company transactions and accounts have been eliminated in the consolidation.

 

Functional Currency / Foreign currency translation — The functional currency of DanDrit USA is the U.S. Dollar. The functional currency of DanDrit Denmark is the Danish Kroner (“DKK”). The Company’s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods ending March 31, 2015 and 2014. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.

 

Cash and Cash Equivalents — The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held in financial institutions in the United States in excess of federally insured amounts of $3,073,967 at March 31, 2015, and had $2,508,759 held in financial institutions in the United States in excess of federally insured amounts at December 31, 2014.

 

Property and Equipment — Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized, upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets which range from four to six years (See Note 3).

 

Intangible Assets — Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board, (“FASB”) Accounting Standards Codification, (“ASC”) Topic 350, “Goodwill and Other Intangible Assets” and amortized the patents on a straight line basis over the estimated useful life of twenty years. Costs incurred in relation to patent applications are capitalized cost and amortized over the estimated useful life of the patent. If it is determined that a patent will not be issued, the related remaining patent application costs are charged to expense.

 

Impairment of Long-Lived Assets — Long-lived assets, such as property, plant, and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.

 

Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values.

 

Revenue Recognition and Sales — The Company’s sales of its MCV colorectal cancer vaccine have been limited to a compassionate use basis in Singapore after stage IIA trials and is not approved for current sale for any other use or location. The Company's accounts for revenue recognition in accordance with the Securities and Exchange Commission Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” (SAB 101), and FASB ASC 605 Revenue Recognition. The Company recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement, product has been shipped or delivered to the customer, the price and terms are finalized, and collections of resulting receivable is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer.

 

Value Added Tax — In Denmark, Value Added Tax (“VAT”) of 25% of the invoice amount is collected in respect of the sales of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices these amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying financial statements.

 

Research and Development Cost — The Company expenses research and development costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of our MAGE –A dendrite cell cancer therapy. Research and development costs were included in operating expenses for the three month periods ended March 31, 2015 and 2014, totaled $151,813, and $0, respectively. Our research and development expenses may fluctuate substantially from quarter to quarter depending on the clinical studies and the timing of samples supporting the clinical studies.

 

Income Taxes — The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes. This statement requires an asset and liability approach for accounting for income taxes.

 

Loss Per Share — The Company calculates earnings /(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of common shares outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive common shares. Potential common shares included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised.

 

Fair Value of Financial Instruments — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

  Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

 

  Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

 

  Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.

 

Accounting Estimates — The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated.

 

Recent Accounting Pronouncements — In February 2015, the FASB issued Accounting Standards Update No. 2015-02 (ASU 2015-02) "Consolidation (Topic 810): Amendments to the Consolidation Analysis." ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We do not anticipate that the adoption of ASU 2015-02 will have any impact on our consolidated financial statements.

 

Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company's present or future financial statements.

 

Reclassification — The financial statements for the period ended March 31, 2014 and December 31, 2014 have been reclassified to conform to the headings and classifications used in the March 31, 2015 financial statements.

v2.4.1.9
Property and Equipment
3 Months Ended
Mar. 31, 2015
Property and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

NOTE 2 — PROPERTY AND EQUIPMENT

 

Property and equipment consisted of the following at March 31, 2015 and December 31, 2014:

 

  Useful Life March 31, 
2015
  December 31, 
2014
 
Lab equipment and instruments 4-6 $208,823  $208,823 
Computer equipment 4-6  60,670   60,670 
     269,493   269,493 
Less Accumulated Depreciation    (269,493)  (269,493)
Net Property and Equipment   $-  $- 

 

Depreciation expense amounted to $0 and $523 for the three month period ended March 31, 2015 and 2014, respectively.

v2.4.1.9
Definite Life Intangible Assets
3 Months Ended
Mar. 31, 2015
Definite Life Intangible Assets [Abstract]  
DEFINITE-LIFE INTANGIBLE ASSETS

NOTE 3 — DEFINITE-LIFE INTANGIBLE ASSETS

 

At March 31, 2015 and December 31, 2014, definite-life intangible assets, net of accumulated amortization, consist of patents on the Company’s products and processes of $161,062 and $186,414, respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization expense for the three months ended March 31, 2015 and 2014 was $4,055 and $6,794. Expected future amortization expense for the years ended are as follows:

 

Year ending December 31,   
2015 $11,462 
2016  15,366 
2017  15,324 
2018  15,324 
2019  15,324 
Thereafter  88,262 
  $161,062 
v2.4.1.9
Notes Payable - Related Party
3 Months Ended
Mar. 31, 2015
Notes Payable - Related Party [Abstract]  
NOTES PAYABLE - RELATED PARTY

NOTE 4 — NOTES PAYABLE – RELATED PARTY

 

Notes payable to related parties consists of the following as of March 31, 2015 and December 31, 2014:

 

  March 31, 
2015
  Dec. 31, 
2014
 
Non-Interest Bearing Loan Payable Sunrise Financial Group Inc. $38,235  $38,235 
Note Payable ML Group  16,777   18,963 
6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC  44,293   42,753 
Total Notes Payable – Related Party  99,305   99,951 
Less Current Maturities  (99,305)  (99,951)
Note Payables – Related Party Long Term $-  $- 

 

The following represents the future maturities of long-term debt as of March 31, 2015:

 

Year ending December 31,   
2015  99,305 
2016  - 
2017  - 
2018  - 
2019  - 
Thereafter  - 
   99,305 

 

On February 15, 2014 and March 18, 2014, DanDrit Denmark received DKK 2,500,000 ($461,084) and DKK 2,300,000 ($424,198) loans (the “2014 Loans”), respectively, from Paseco ApS, an entity owned by a shareholder of the Company (“Paseco”). The 2014 Loans were payable 14 days after the completion of the contemplated public offering in DanDrit USA or February 1, 2015, and accrued interest at 5% per annum. On April 29, 2014, DanDrit Denmark and Paseco entered into an amendment whereby the terms of the 2014 Loans were payable on February 1, 2015 and could be extended at the Company’s option for an additional year with an increase in the interest rate to 7.00%. As of October 17, 2014, the outstanding balance on the 2014 Loans including accrued interest was $836,830 based on the currency exchange rate of October 17, 2014. On October 17, 2014 the Company repaid the loan and interest in its entirety.

 

DanDrit Denmark has received an unsecured loan facility from Sune Olsen Holding ApS (“Sune Olsen Holding”), a shareholder of the Company, with a goal of ensuring financing until new equity is invested in the Company. Under the loan facility DanDrit Denmark has received the following amounts: on November 11, 2013 DKK 1,500,000 ($276,651), on November 20, 2013 DKK 405,000 ($74,696), and on December 2, 2013 DKK 900,000 ($165,990). The loans were due May 1, 2014 and accrued interest at 5% per year. During March 2014, the Company extended maturity date of the loans with Sune Olsen Holdings from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit USA or February 1, 2015. On November 26, 2014, the Company repaid the loan facility and interest thereon.

 

DanDrit Denmark has received an unsecured loan from Sune Olsen, managing member of Sune Olsen Holding, with a goal of ensuring financing until new equity is invested in the Company. The loan in the amount of DKK 1,000,000 ($184,434) was issued on December 20, 2013. The loan was due May 1, 2014 and accrued interest of 5% per year. During March 2014, the Company extended the maturity date of the DKK 1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit USA or February 1, 2015. On November 26, 2014 the Company repaid the unsecured loan and interest thereon.

 

During March 2014, the Company received a 2,000,000 DKK letter of support from Paseco committing to the additional financing to ensure continued operations until February 1, 2015. The letter expired on February 1, 2015.

 

As of March 31, 2015, the outstanding balance of $38,235 for professional fees paid by a related party and amounts advanced to the Parent are reported as loan payable - related party. The $38,235 loan payable was acquired in the reverse acquisition. The amount is unsecured, non-interest bearing and has no stipulated repayment terms.

 

A 6% Promissory Note payable (the “Note”) to NLBDIT 2010 Enterprises, LLC, an entity controlled by a shareholder of the Company, was acquired by the Company in the reverse acquisition, payable on February 12, 2014 upon the completion date of the Share Exchange. As of March 31, 2015 and 2014, the outstanding balance on the Note, including accrued interest, was $44,293 and $41,945. During the three months ended March 31, 2015 and 2014 the Company recorded related party interest on the Note of $579, and $579.

v2.4.1.9
Leases
3 Months Ended
Mar. 31, 2015
Leases [Abstract]  
LEASES

NOTE 5 — LEASES

 

Operating Leases — The Company leases laboratory and production space under operating lease agreements which can be cancelled with 3 month notice. The lease calls for monthly payments of DKK 6,000 (approximately $906 at March 31, 2015).

 

Lease expense charged to operations was $11,918 and, $7,255 for the three months ended March 31, 2015 and 2014, respectively.

 

On March 27, 2014, the Company entered into an operating lease agreement for office space from a related party. The Lease calls for monthly payments of DKK 10,000 (approximately $1,579), increasing to DKK 20,000 (approximately $3,393) on July 1, 2014. The lease can be terminated by either the Company or the landlord by giving the other 3 months notice. The Company gave notice terminating the lease agreement on February 27, 2015 thereby releasing the Company from the lease on May 31, 2015.

v2.4.1.9
Income Taxes
3 Months Ended
Mar. 31, 2015
Income Taxes [Abstract]  
INCOME TAXES

NOTE 6 — INCOME TAXES

 

The Company accounts for income taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and any available operating loss or tax credit carry forwards. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which cannot be determined.

 

As of March 31, 2015, the Company had net operating loss carry-forwards of approximately $2,416,813 for Danish tax purposes which do not expire and net operating loss carry-forwards of approximately $179,661 for U.S. Federal Tax purposes which expire through 2034, a portion of which shall be limited due to the change in control of the Parent.

 

The Company files U.S. and Danish income tax returns, and they are generally no longer subject to tax examinations for years prior to 2011 and 2008, respectively.

 

The temporary differences, tax credits and carry forwards gave rise to the following deferred tax asset (liabilities) at March 31, 2015 and December 31, 2014:

 

    March 31,
2015
    December 31, 
2014
 
Excess of Tax over book depreciation Fixed assets   $ 12,711     $ 12,711  
Excess of Tax over book depreciation Patents     52,041       52,041  
Net Operating Loss Carry forward     2,416,813       2,380,106  
Valuation Allowance     (2,481,565 )     (2,444,858 )
Total Deferred Tax Asset (Liabilities)   $ -     $ -  

 

In accordance with prevailing accounting guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is to determine whether the tax position meet the more-likely-than-not condition for recognition and the second step is to determine the amount to be recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is more likely than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation allowance was recorded for all deferred tax assets.

  

A reconciliation of income tax expense at the federal statutory rate to income tax expense at the Company’s effective rate is as follows at March 31, 2015 and 2014:

 

    March 31, 2015     March 31, 2014  
Computed Tax at Expected Statutory Rate   $ (277,657 )   $ (144,858 )
Non-US Income Taxed at Different Rates     97,996       44,858  
Non-Deductable expenses     -       -  
Valuation allowance     179,661       100,000  
Income Tax Expense   $ -     $ -  

 

The components of income tax expense (benefit) from continuing operations for the three months ended March 31, 2015 and 2014 consisted of the following

 

    2015     2014  
Current Tax Expense            
Danish Income Tax   $ -     $ -  
Total Current Tax Expense     -       -  
Deferred Income Tax Expense (Benefit)                
Excess of Tax over Book Depreciation Fixed Assets     -       -  
Excess of Tax over Book Depreciation Patents     -       -  
Net Operating Loss Carry forwards     (179,661 )     (100,000 )
Change in the Valuation allowance     179,661       100,000  
Total Deferred Tax Expense   $ -     $ -  

 

Deferred income tax expense / (benefit) results primarily from the reversal of temporary timing differences between tax and financial statement income.

v2.4.1.9
Loss Per Share
3 Months Ended
Mar. 31, 2015
Loss Per Share [Abstract]  
LOSS PER SHARE

NOTE 7 — LOSS PER SHARE

 

The following data shows the amounts used in computing loss per share and the effect on income and the weighted average number of shares of potential dilutive common stock for the three month period ended March 31, 2015, and 2014:

 

  For the Three 
Months Ended
 
  March 31, 
  2015  2014 
Net (Loss)  (1,253,345)  (426,054)
Weighted average number of common shares used in basic earnings per share  9,533,290   6,880,278 
Effect of dilutive securities, stock options and warrants  -   - 
Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share  9,533,290   6,880,278 

 

For the three months ended March 31, 2015 and 2014, the Company had no common stock equivalents.

v2.4.1.9
Stockholder's Equity
3 Months Ended
Mar. 31, 2015
Stockholder's Equity [Abstract]  
STOCKHOLDERS' EQUITY

NOTE 8 — STOCKHOLDERS’ EQUITY

 

Common Stock — The Company has 100,000,000 authorized shares of Common stock $0.0001. As of March 31, 2015 and December 31, 2014 there were 9,533,290 shares issued and outstanding, respectively.

 

Common Stock Issuances — On December 31, 2014, the Company received $2,000,000 in connection with a private offering of 400,000 shares of common stock at an offering price of $5.00 per share.

 

During the year ended December 31, 2014, pursuant to the Company’s offering of up to $12,000,000 (2,400,000 shares) of common stock at an offering price of $5.00 per share in an initial public offering pursuant to a registration statement effective on August 12, 2014, the Company sold 1,093,290 shares of common stock for gross proceeds of $5,466,450 less offering costs of $156,360.

 

Share Exchange Agreement/Reverse Acquisition — On February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement (the "Share Exchange Agreement"), we completed the acquisition of 100% of the issued and outstanding capital stock  of  DanDrit Denmark (the “Share Exchange”) and as a result became DanDrit Denmark’s parent company (the “Parent”). In connection with the Share Exchange, each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of DanDrit USA’s common stock, par value $.0001 per share (the “Common Stock”) for an aggregate of 6,000,000 shares, including 185,053 shares of Common Stock reserved for issuance, in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, to the DanDrit Denmark shareholders who did not consent to the Share Exchange and deemed issued and outstanding for accounting purposes. In addition, in connection with the Share Exchange (1) the sole shareholder prior to the Share Exchange agreed to cancel 4,400,000 shares of outstanding Common Stock owned by it and (2) the board of directors and executive management of DanDrit Denmark was appointed to serve as the Board of Directors and executive management of DanDrit USA effective upon the resignation of the sole officer and director of DanDrit USA prior to the closing of the Share Exchange.

 

On February 11, 2014 1,400,000 and 40,000 common shares of the Company were issued for consulting and legal services valued at $5 per share or $7,000,000 and $200,000, respectively. These shares were issued by the Company prior to the reverse acquisition of DanDrit Denmark and the $7,200,000 was closed out to additional paid in capital in connection with the recapitalization of DanDrit Denmark.

 

On February 12, 2014, upon the closing of the Share Exchange, the Company and the its majority shareholder immediately prior to the closing agreed to cancel up to 4,400,000 shares of our common stock. In addition, following the closing of the Share Exchange, DanDrit Biotech USA, Inc., a wholly owned subsidiary of the Company merged with and into the Company, thereby changing the Company’s name to “DanDrit Biotech USA, Inc.”

 

Voting — Holders of the Company’s common stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the election of directors, and do not have any right to cumulate votes in the election of directors.

 

 

Dividends — Holders of the Company’s common stock are entitled to receive ratably such dividends as our Board of Directors from time to time may declare out of funds legally available.

 

Liquidation Rights — In the event of any liquidation, dissolution or winding-up of affairs of the Company, after payment of all of our debts and liabilities, the holders of the Company’s common stock will be entitled to share ratably in the distribution of any of our remaining assets.

v2.4.1.9
Commitments and Contingencies
3 Months Ended
Mar. 31, 2015
Commitments and Contingencies [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 9 — COMMITMENTS AND CONTINGENCIES

 

Shares held for non-consenting shareholders – In connection with the Share Exchange agreement certain shareholders of Dandrit Denmark had not been identified or did not consent to the exchange of shares. In accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, the Non-Consenting Shareholders that did not exchange the DanDrit Denmark equity interests owned by such Non-Consenting Shareholders for shares of the Company, will be entitled to receive up to 185,053 shares of common stock of the Company that each such Non-Consenting Shareholder would have been entitled to receive if such shareholder had consented to the Share Exchange. The 185,053 shares have been reflected as issued and outstanding in the accompanying financial statements.

 

Clinical Trial Agreement - On October 1, 2014 the Company’s subsidiary, DanDrit Biotech A/S signed a contract of collaboration with the University Hospital IRCCS “San Martino” - IST – National Institute for Cancer Research, known as the San Martino Hospital of Genoa. Dr. Alberto Sobrero, the Head of the Medical Oncology Unit at the San Martino Hospital, is principal investigator of the randomized multicenter study. The collaboration relates to a Phase III adjuvant study of DanDrit’s vaccine in patients with no evident disease (“NED”) stage IV colorectal cancer (“CRC”). The primary goal of the study is to evaluate the efficacy of DanDrit’s MelCancerVac® (“MCV”) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices.

 

Patient Name Use Program — On December 16, 2013, DanDrit Denmark entered into an agreement with a Dutch company (the “MCV Partner”) regarding a Patient Name Use Program (PNU) for the Company’s MCV. This program will allow DanDrit Denmark to sell MCV for a year of treatment (10 vaccines) to cancer patients through the MCV Partner. The MCV Partner offers a worldwide online platform providing access to non-registered medicines for patients with life threatening diseases. The MCV Partner is a turnkey solution and will be in charge of regulatory, recruitment, logistics, and pharmaco vigilance. The Company will pay the MCV Partner a royalty on a country to country basis for 20 years on MCV sales sold under the agreement. Either party may terminate the agreement with 180 days written notice.

 

Food and Drug Administration (FDA) — The FDA has extensive regulatory authority over biopharmaceutical products (drugs and biological products), manufacturing protocols and procedures and the facilities in which they will be manufactured. Any new bio product intended for use in humans is subject to rigorous testing requirements imposed by the FDA with respect to product efficacy and safety, possible toxicity and side effects. FDA approval for the use of new bio products (which can never be assured) requires several rounds of extensive preclinical testing and clinical investigations conducted by the sponsoring pharmaceutical company prior to sale and use of the product. At each stage, the approvals granted by the FDA include the manufacturing process utilized to produce the product. Accordingly, the Company’s cell systems used for the production of therapeutic or bio therapeutic products are subject to significant regulation by the FDA under the Federal Food, Drug and Cosmetic Act, as amended.

 

Product liability — The contract production services for therapeutic products offered exposes an inherent risk of liability as bio therapeutic substances manufactured, at the request and to the specifications of customers, could foreseeably cause adverse effects. The Company seeks to obtain agreements from contract production customers indemnifying and defending the Company from any potential liability arising from such risk. There can be no assurance, however, that the Company will be successful in obtaining such agreements in the future or that such indemnification agreements will adequately protect the Company against potential claims relating to such contract production services. The Company may also be exposed to potential product liability claims by users of its products. A successful partial or completely uninsured claim against the Company could have a material adverse effect on the Company’s operations.

 

Employment Agreements — The Company and its Subsidiary have employment agreements with officers of the Company.

 

Contingencies — The Company is from time to time involved in routine legal and administrative proceedings and claims of various types. While any proceedings or claim contains an element of uncertainty, management does not expect a material impact on our results of operations or financial position.

 

Consulting Agreement  As of December 11, 2014, the Company entered into an agreement with Northern Biotech Fund SARL, an entity controlled by a shareholder of the Company. Northern Biotech Fund SARL provides consulting services to the Company in connection with planning and structuring a fund raising for the Company. In 2014 consultancy expenses were $148,395 and for the three month ended March 31, 2015 the consultancy expenses were $240,000.

v2.4.1.9
Related Party Transactions
3 Months Ended
Mar. 31, 2015
Related Party Transactions [Abstract]  
Related Party Transactions

NOTE 10 — Related Party Transactions

 

During the three month ended March 31, 2015 and 2014, the Company entered into various notes payable with shareholders of the Company (See Note 4).

 

On March 27, 2014 the Company entered into an operating lease agreement for office space from a shareholder of the Company (See Note 5). During the three months ended March 31, 2015 and 2014, the Company paid the related party DKK60,000 and DKK 0 or approximately $3,019 and $0, respectively.

 

During the three months ended March 31, 2015 and 2014, a law firm partially owned by the Company’s Chairman of the Board of Directors provided legal services of $60,381 and $100,912, respectively, to the Company. At March 31, 2015 and December 31, 2014, the Company had a payable to the firm in the amount of $200,857 and $212,438, respectively.

 

As of December 11, 2014, the Company entered into an agreement with Northern Biotech Fund SARL, an entity controlled by a shareholder of the Company. Northern Biotech Fund SARL provides consulting services to the Company in connection with planning and structuring a fund raising for the Company. During the three months ended March 31, 2015 and 2014 the Company expensed $240,000 and $0 under the agreement.

v2.4.1.9
Subsequent Event
3 Months Ended
Mar. 31, 2015
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 11 — SUBSEQUENT EVENTS

 

The Company’s management reviewed material events through May 13, 2015.

 

On April 28, 2015 Robert Wolfe resigned as Chief Financial Officer of the Company and on May 1st, the Board appointed Lone Degn as the Chief Financial Officer of the Company.

 

On April 28, 2015 the Company entered into a service agreement with Fondazione Giscad per la Ricerca sui Tumori to support Dandrit in a clinical trial to be conducted in Italy.

 

On April 1st, 2015 DanDrit entered into a project agreement with IRCCS Azienda Ospedaliera Univeritaria San Martino IST- Istituto Nazionale per la ricerca sul Cancro to perform certain services with respect to a multicenter clinical trial.

 

On April 23, 2015, the Company entered into a collaboration agreement with Riyadh Pharma in Saudi Arabia to promote cooperation in the manufacturing and marketing of DanDrit's dendritic cell cancer vaccine.

v2.4.1.9
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2015
Summary of Significant Accounting Policies [Abstract]  
Business and Basis of Presentation

Business and Basis of Presentation — DanDrit Biotech USA, Inc. (“DanDrit USA”, the “Company”, “we”, “us”, “our”) (formerly Putnam Hills Corp) was originally incorporated in the state of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business.

 

DanDrit BioTech A/S, a Danish Corporation was incorporated on April 1, 2001 (“DanDrit Denmark”) a 96,92% owned subsidiary of the Company. The Company engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the human treatment of cancer using the dendritic cell technology.

Reverse Acquisition

Reverse Acquisition — On February 12, 2014, pursuant to the Share Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA completed the acquisition of 100% of the issued and outstanding capital stock of DanDrit Denmark (the “Share Exchange”) and as a result became DanDrit Denmark’s parent company (the “Parent”). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the “Common Stock”) of Parent outstanding. Parent and an existing shareholder agreed to cancel 4,400,000 shares of its Common Stock and issued 1,440,000 shares of Common Stock for legal and consulting services related to the Share Exchange and a future public offering. At the time of the Share Exchange each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of Parent’s Common Stock, for a total of 6,000,000 shares, resulting in 8,040,000 shares of the Parent’s Common Stock outstanding immediately following the Share Exchange, including 185,053 shares of Common Stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the DanDrit Denmark shareholders who have not consented to the Share Exchange (the “Non-Consenting Shareholders”), and deemed issued and outstanding for accounting purposes.

Consolidation

Consolidation — For the three months ended March 31, 2015 and 2014, the consolidated financial statements include the accounts and operations of the DanDrit Denmark, and the accounts and operations of DanDrit USA. All material inter-company transactions and accounts have been eliminated in the consolidation.

Functional Currency / Foreign currency translation

Functional Currency / Foreign currency translation — The functional currency of DanDrit USA is the U.S. Dollar. The functional currency of DanDrit Denmark is the Danish Kroner (“DKK”). The Company’s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods ending March 31, 2015 and 2014. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.

Cash and Cash Equivalents
Cash and Cash Equivalents — The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held in financial institutions in the United States in excess of federally insured amounts of $3,073,967 at March 31, 2015, and had $2,508,759 held in financial institutions in the United States in excess of federally insured amounts at December 31, 2014.
Property and Equipment

Property and Equipment — Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized, upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets which range from four to six years (See Note 3).

Intangible Assets

Intangible Assets — Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board, (“FASB”) Accounting Standards Codification, (“ASC”) Topic 350, “Goodwill and Other Intangible Assets” and amortized the patents on a straight line basis over the estimated useful life of twenty years. Costs incurred in relation to patent applications are capitalized cost and amortized over the estimated useful life of the patent. If it is determined that a patent will not be issued, the related remaining patent application costs are charged to expense.

Impairment of Long-Lived Assets

 

Impairment of Long-Lived Assets — Long-lived assets, such as property, plant, and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.

 

Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values.

Revenue Recognition and Sales

 

Revenue Recognition and Sales — The Company’s sales of its MCV colorectal cancer vaccine have been limited to a compassionate use basis in Singapore after stage IIA trials and is not approved for current sale for any other use or location. The Company's accounts for revenue recognition in accordance with the Securities and Exchange Commission Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” (SAB 101), and FASB ASC 605 Revenue Recognition. The Company recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement, product has been shipped or delivered to the customer, the price and terms are finalized, and collections of resulting receivable is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer.

Value Added Tax

 

Value Added Tax — In Denmark, Value Added Tax (“VAT”) of 25% of the invoice amount is collected in respect of the sales of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices these amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying financial statements.

Research and Development Cost
Research and Development Cost — The Company expenses research and development costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of our MAGE –A dendrite cell cancer therapy. Research and development costs were included in operating expenses for the three month periods ended March 31, 2015 and 2014, totaled $151,813, and $0, respectively. Our research and development expenses may fluctuate substantially from quarter to quarter depending on the clinical studies and the timing of samples supporting the clinical studies.
Income Taxes

 

Income Taxes — The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes. This statement requires an asset and liability approach for accounting for income taxes.

Loss Per Share

Loss Per Share — The Company calculates earnings /(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of common shares outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive common shares. Potential common shares included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised.

Fair Value of Financial Instruments

 

Fair Value of Financial Instruments — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

 Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

 

 Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

 

 Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.

Accounting Estimates

 

Accounting Estimates — The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated.

Recent Accounting Pronouncements

Recent Accounting Pronouncements — In February 2015, the FASB issued Accounting Standards Update No. 2015-02 (ASU 2015-02) "Consolidation (Topic 810): Amendments to the Consolidation Analysis." ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We do not anticipate that the adoption of ASU 2015-02 will have any impact on our consolidated financial statements.

 

Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Reclassification

Reclassification — The financial statements for the period ended March 31, 2014 and December 31, 2014 have been reclassified to conform to the headings and classifications used in the March 31, 2015 financial statements.

v2.4.1.9
Property and Equipment (Tables)
3 Months Ended
Mar. 31, 2015
Property and Equipment [Abstract]  
Summary of property and equipment

  Useful Life March 31, 
2015
  December 31, 
2014
 
Lab equipment and instruments 4-6 $208,823  $208,823 
Computer equipment 4-6  60,670   60,670 
     269,493   269,493 
Less Accumulated Depreciation    (269,493)  (269,493)
Net Property and Equipment   $-  $- 
v2.4.1.9
Definite Life Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2015
Definite Life Intangible Assets [Abstract]  
Schedule of definite-life intangible assets, future amortization expense
Year ending December 31,   
2015 $11,462 
2016  15,366 
2017  15,324 
2018  15,324 
2019  15,324 
Thereafter  88,262 
  $161,062 
v2.4.1.9
Notes Payable - Related Party (Tables)
3 Months Ended
Mar. 31, 2015
Notes Payable - Related Party [Abstract]  
Summary of notes payable and related parties

  March 31, 
2015
  Dec. 31, 
2014
 
Non-Interest Bearing Loan Payable Sunrise Financial Group Inc. $38,235  $38,235 
Note Payable ML Group  16,777   18,963 
6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC  44,293   42,753 
Total Notes Payable – Related Party  99,305   99,951 
Less Current Maturities  (99,305)  (99,951)
Note Payables – Related Party Long Term $-  $- 
Schedule of maturities of long term debt
Year ending December 31,   
2015  99,305 
2016  - 
2017  - 
2018  - 
2019  - 
Thereafter  - 
   99,305 
v2.4.1.9
Income Taxes (Tables)
3 Months Ended
Mar. 31, 2015
Income Taxes [Abstract]  
Summary of deferred tax asset (liabilities)

  March 31,
2015
  December 31, 
2014
 
Excess of Tax over book depreciation Fixed assets $12,711  $12,711 
Excess of Tax over book depreciation Patents  52,041   52,041 
Net Operating Loss Carry forward  2,416,813   2,380,106 
Valuation Allowance  (2,481,565)  (2,444,858)
Total Deferred Tax Asset (Liabilities) $-  $- 

 

Schedule of reconciliation of income tax expense at the federal statutory rate

  March 31, 2015  March 31, 2014 
Computed Tax at Expected Statutory Rate $(277,657) $(144,858)
Non-US Income Taxed at Different Rates  97,996   44,858 
Non-Deductable expenses  -   - 
Valuation allowance  179,661   100,000 
Income Tax Expense $-  $- 
Schedule of components of income tax expense (benefit) from continuing operations

  2015  2014 
Current Tax Expense      
Danish Income Tax $-  $- 
Total Current Tax Expense  -   - 
Deferred Income Tax Expense (Benefit)        
Excess of Tax over Book Depreciation Fixed Assets  -   - 
Excess of Tax over Book Depreciation Patents  -   - 
Net Operating Loss Carry forwards  (179,661)  (100,000)
Change in the Valuation allowance  179,661   100,000 
Total Deferred Tax Expense $-  $- 
v2.4.1.9
Loss Per Share (Tables)
3 Months Ended
Mar. 31, 2015
Loss Per Share [Abstract]  
Schedule of weighted average number of shares of potential dilutive common stock

  For the Three 
Months Ended
 
  March 31, 
  2015  2014 
Net (Loss)  (1,253,345)  (426,054)
Weighted average number of common shares used in basic earnings per share  9,533,290   6,880,278 
Effect of dilutive securities, stock options and warrants  -   - 
Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share  9,533,290   6,880,278 
v2.4.1.9
Summary of Significant Accounting Policies (Details) (USD $)
3 Months Ended 0 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Feb. 12, 2014
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Jan. 18, 2011
Summary of Significant Accounting Policies (Textual)                
Common stock, Par value $ 0.0001us-gaap_CommonStockParOrStatedValuePerShare     $ 0.0001us-gaap_CommonStockParOrStatedValuePerShare        
Shares of parent common stock outstanding                      
Common Stock reserved for issuance 185,053us-gaap_CommonStockCapitalSharesReservedForFutureIssuance              
Balances held in financial institutions $ 3,073,967us-gaap_CashFDICInsuredAmount     $ 2,508,759us-gaap_CashFDICInsuredAmount        
Value added tax percentage 25.00%pmhs_ValueAddedTaxPercentage              
Value added tax paid to Danish and EU vendors 25.00%pmhs_ValueAddedTaxPaidToVendors              
Research and development expense $ 151,813us-gaap_ResearchAndDevelopmentExpense               
Owned subsidiary percentage 96.92%us-gaap_MinorityInterestOwnershipPercentageByParent              
Parent Company [Member]                
Summary of Significant Accounting Policies (Textual)                
Share exchange agreement acquisition percentage     97.00%pmhs_ShareExchangeAgreementAcquisitionPercentage
/ dei_LegalEntityAxis
= us-gaap_ParentCompanyMember
         
Common stock, Par value     $ 0.0001us-gaap_CommonStockParOrStatedValuePerShare
/ dei_LegalEntityAxis
= us-gaap_ParentCompanyMember
         
Common Stock reserved for issuance     185,053us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
/ dei_LegalEntityAxis
= us-gaap_ParentCompanyMember
         
Common Stock [Member]                
Summary of Significant Accounting Policies (Textual)                
Shares prior to share exchange agreement 5,000,000pmhs_ShareExchangeAgreementCommonStockShares
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
             
Share exchange agreement number of share cancellation     4,400,000pmhs_ShareExchangeAgreementNumberOfShareCancellation
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
         
Common shares issued for legal and consulting services 1,440,000pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
             
Share exchange agreement shares held by consenting shareholders of company 1.498842pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
             
Shares of parent common stock outstanding 8,185,100us-gaap_SharesOutstanding
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
    6,000,000us-gaap_SharesOutstanding
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
6,000,000us-gaap_SharesOutstanding
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
5,318,151us-gaap_SharesOutstanding
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
   
Common Stock [Member] | Parent Company [Member]                
Summary of Significant Accounting Policies (Textual)                
Share exchange agreement acquisition percentage     100.00%pmhs_ShareExchangeAgreementAcquisitionPercentage
/ dei_LegalEntityAxis
= us-gaap_ParentCompanyMember
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
         
Share exchange agreement shares issued to parent company     6,000,000pmhs_ShareExchangeAgreementSharesIssuedToParentCompany
/ dei_LegalEntityAxis
= us-gaap_ParentCompanyMember
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
         
Shares of parent common stock outstanding 8,040,000us-gaap_SharesOutstanding
/ dei_LegalEntityAxis
= us-gaap_ParentCompanyMember
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
             
v2.4.1.9
Property and Equipment (Details) (USD $)
3 Months Ended
Mar. 31, 2015
Dec. 31, 2014
Property, Plant and Equipment [Line Items]    
Gross Property and Equipment 269,493us-gaap_PropertyPlantAndEquipmentGross $ 269,493us-gaap_PropertyPlantAndEquipmentGross
Less: Accumulated Depreciation (269,493)us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment 269,493us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
Net Property and Equipment      
Lab equipment and instruments [Member]    
Property, Plant and Equipment [Line Items]    
Gross Property and Equipment 208,823us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= pmhs_LabEquipmentAndInstrumentsMember
208,823us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= pmhs_LabEquipmentAndInstrumentsMember
Lab equipment and instruments [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated useful life (years) 6 years  
Lab equipment and instruments [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated useful life (years) 4 years  
Computer equipment [Member]    
Property, Plant and Equipment [Line Items]    
Gross Property and Equipment    $ 60,670us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_ComputerEquipmentMember
Computer equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated useful life (years) 6 years  
Computer equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated useful life (years) 4 years  
v2.4.1.9
Property and Equipment (Details Textual) (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Property and Equipment (Textual)    
Depreciation expense $ 0us-gaap_Depreciation $ 523us-gaap_Depreciation
v2.4.1.9
Definite Life Intangible Assets (Details) (USD $)
Mar. 31, 2015
Dec. 31, 2014
Definite Life Intangible Assets [Abstract]    
2015 $ 11,462us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths  
2016 15,366us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo  
2017 15,324us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree  
2018 15,324us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour  
2019 15,324us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive  
Thereafter 88,262us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive  
Finite-Lived Intangible Assets, Net $ 161,062us-gaap_FiniteLivedIntangibleAssetsNet $ 186,414us-gaap_FiniteLivedIntangibleAssetsNet
v2.4.1.9
Definite Life Intangible Assets (Details Textual) (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Dec. 31, 2014
Definite Life Intangible Assets (Textual)      
Finite-Lived Intangible Assets, Net $ 161,062us-gaap_FiniteLivedIntangibleAssetsNet   $ 186,414us-gaap_FiniteLivedIntangibleAssetsNet
Amortization expense $ 4,055us-gaap_AdjustmentForAmortization $ 6,794us-gaap_AdjustmentForAmortization  
v2.4.1.9
Notes Payable - Related Party (Details) (USD $)
Mar. 31, 2015
Dec. 31, 2014
Related Party Transaction [Line Items]    
Notes Payable - Related Party $ 99,305us-gaap_NotesPayableRelatedPartiesClassifiedCurrent $ 99,951us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
Less Current Maturities (99,305)us-gaap_LongTermDebtCurrent (99,351)us-gaap_LongTermDebtCurrent
Note Payables - Related Party Long Term      
Non Interest Bearing Loan Payable Sunrise Financial Group Inc [Member]    
Related Party Transaction [Line Items]    
Notes Payable - Related Party 38,235us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember
38,235us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember
Note Payable ML Group [Member]    
Related Party Transaction [Line Items]    
Notes Payable - Related Party 16,777us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_NotePayableMlGroupMember
18,963,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_NotePayableMlGroupMember
6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC [Member]    
Related Party Transaction [Line Items]    
Notes Payable - Related Party $ 44,293us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember
$ 42,753us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember
v2.4.1.9
Notes Payable - Related Party (Details 1) (USD $)
Mar. 31, 2015
Notes Payable - Related Party [Abstract]  
2015 $ 99,305us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2016   
2017   
2018   
2019   
Thereafter   
Total long term debt $ 99,305us-gaap_LongTermDebt
v2.4.1.9
Notes Payable - Related Party (Details Textual)
0 Months Ended 3 Months Ended
Mar. 31, 2015
USD ($)
Dec. 02, 2013
Sune Olsen Holding Aps [Member]
Loan One [Member]
USD ($)
Dec. 02, 2013
Sune Olsen Holding Aps [Member]
Loan One [Member]
DKK
Nov. 20, 2013
Sune Olsen Holding Aps [Member]
Loan One [Member]
USD ($)
Nov. 20, 2013
Sune Olsen Holding Aps [Member]
Loan One [Member]
DKK
Nov. 11, 2013
Sune Olsen Holding Aps [Member]
Loan One [Member]
USD ($)
Nov. 11, 2013
Sune Olsen Holding Aps [Member]
Loan One [Member]
DKK
Dec. 20, 2013
Sune Olsen Holding Aps [Member]
Loan Two [Member]
USD ($)
Dec. 20, 2013
Sune Olsen Holding Aps [Member]
Loan Two [Member]
DKK
Mar. 18, 2014
Paseco Aps [Member]
Loan [Member]
USD ($)
Mar. 18, 2014
Paseco Aps [Member]
Loan [Member]
DKK
Feb. 15, 2014
Paseco Aps [Member]
Loan [Member]
USD ($)
Feb. 15, 2014
Paseco Aps [Member]
Loan [Member]
DKK
Mar. 31, 2014
Paseco Aps [Member]
Loan Three [Member]
DKK
Mar. 31, 2015
Nlbdit Two Zero One Zero Enterprises, Llc [Member]
Loan Ten [Member]
USD ($)
Mar. 31, 2014
Nlbdit Two Zero One Zero Enterprises, Llc [Member]
Loan Ten [Member]
USD ($)
Related Party Transaction [Line Items]                                
Unsecured loan $ 38,235us-gaap_UnsecuredDebt $ 165,990us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= pmhs_LoanOneMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_SuneOlsenHoldingApsMember
900,000us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= pmhs_LoanOneMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_SuneOlsenHoldingApsMember
$ 74,696us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= pmhs_LoanOneMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_SuneOlsenHoldingApsMember
405,000us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= pmhs_LoanOneMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_SuneOlsenHoldingApsMember
$ 276,651us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= pmhs_LoanOneMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_SuneOlsenHoldingApsMember
1,500,000us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= pmhs_LoanOneMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_SuneOlsenHoldingApsMember
$ 184,434us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= pmhs_LoanTwoMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_SuneOlsenHoldingApsMember
1,000,000us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= pmhs_LoanTwoMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_SuneOlsenHoldingApsMember
$ 424,198us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_UnsecuredDebtMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_PasecoApsMember
2,300,000us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_UnsecuredDebtMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_PasecoApsMember
$ 461,084us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_UnsecuredDebtMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_PasecoApsMember
2,500,000us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_UnsecuredDebtMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_PasecoApsMember
2,000,000us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= pmhs_LoanThreeMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_PasecoApsMember
$ 44,293us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= pmhs_LoanTenMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember
$ 41,945us-gaap_UnsecuredDebt
/ us-gaap_LongtermDebtTypeAxis
= pmhs_LoanTenMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember
Accrued interest in percentage                   5.00%pmhs_AccruedInterestInPercentage
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_UnsecuredDebtMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_PasecoApsMember
5.00%pmhs_AccruedInterestInPercentage
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_UnsecuredDebtMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_PasecoApsMember
5.00%pmhs_AccruedInterestInPercentage
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_UnsecuredDebtMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_PasecoApsMember
5.00%pmhs_AccruedInterestInPercentage
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_UnsecuredDebtMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_PasecoApsMember
     
Interest expense, borrowing loans                             579us-gaap_InterestExpenseOtherShortTermBorrowings
/ us-gaap_LongtermDebtTypeAxis
= pmhs_LoanTenMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember
579us-gaap_InterestExpenseOtherShortTermBorrowings
/ us-gaap_LongtermDebtTypeAxis
= pmhs_LoanTenMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember
Increased interest percentage                   7.00%us-gaap_DebtInstrumentInterestRateEffectivePercentage
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_UnsecuredDebtMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_PasecoApsMember
7.00%us-gaap_DebtInstrumentInterestRateEffectivePercentage
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_UnsecuredDebtMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_PasecoApsMember
7.00%us-gaap_DebtInstrumentInterestRateEffectivePercentage
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_UnsecuredDebtMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_PasecoApsMember
7.00%us-gaap_DebtInstrumentInterestRateEffectivePercentage
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_UnsecuredDebtMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_PasecoApsMember
  6.00%us-gaap_DebtInstrumentInterestRateEffectivePercentage
/ us-gaap_LongtermDebtTypeAxis
= pmhs_LoanTenMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember
 
Debt Instrument, Maturity Date                           Feb. 01, 2015    
Extended maturity date, Description               The Company extended maturity date of the DKK 1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit Biotech USA, Inc. or February 1, 2015. The Company extended maturity date of the DKK 1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit Biotech USA, Inc. or February 1, 2015.              
Loans payable $ 38,235us-gaap_LoansPayable                              
v2.4.1.9
Leases (Details)
3 Months Ended 1 Months Ended
Mar. 31, 2015
USD ($)
Mar. 31, 2014
USD ($)
Mar. 31, 2015
Lab space [Member]
USD ($)
Mar. 31, 2015
Lab space [Member]
DKK
Mar. 27, 2014
Office space [Member]
USD ($)
Mar. 27, 2014
Office space [Member]
DKK
Jul. 01, 2014
Office space [Member]
Subsequent Event [Member]
USD ($)
Jul. 01, 2014
Office space [Member]
Subsequent Event [Member]
DKK
Operating Leased Assets [Line Items]                
Rental payments for Operating Leases $ 11,918us-gaap_OperatingLeasesRentExpenseNet $ 7,255us-gaap_OperatingLeasesRentExpenseNet $ 906us-gaap_OperatingLeasesRentExpenseNet
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= pmhs_LeasedLaboratorySpaceMember
6,000us-gaap_OperatingLeasesRentExpenseNet
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= pmhs_LeasedLaboratorySpaceMember
$ 1,579us-gaap_OperatingLeasesRentExpenseNet
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= pmhs_LeasedOfficeSpaceMember
10,000us-gaap_OperatingLeasesRentExpenseNet
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= pmhs_LeasedOfficeSpaceMember
$ 3,393us-gaap_OperatingLeasesRentExpenseNet
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= pmhs_LeasedOfficeSpaceMember
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
20,000us-gaap_OperatingLeasesRentExpenseNet
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= pmhs_LeasedOfficeSpaceMember
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
v2.4.1.9
Income Taxes (Details) (USD $)
Mar. 31, 2015
Dec. 31, 2014
Summary of effective income tax rate reconciliation    
Excess of Tax over book depreciation Fixed assets $ 12,711pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets $ 12,711pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets
Excess of Tax over book depreciation Patents 52,041pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents 52,041pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents
Net Operating Loss Carry forward 2,416,813us-gaap_DeferredTaxAssetsOperatingLossCarryforwards 2,380,106us-gaap_DeferredTaxAssetsOperatingLossCarryforwards
Valuation Allowance (2,481,565)us-gaap_DeferredTaxAssetsValuationAllowance (2,444,858)us-gaap_DeferredTaxAssetsValuationAllowance
Total Deferred Tax Asset (Liabilities)      
v2.4.1.9
Income Taxes (Details 1) (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Income Tax Reconciliation Expense Benefit    
Computed Tax at Expected Statutory Rate $ (277,657)pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit $ (144,858)pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit
Non-US Income Taxed at Different Rates 97,996pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit 44,858pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit
Non-Deductible expenses      
Valuation allowance 179,661pmhs_IncomeTaxReconciliationValuationAllowance 100,000pmhs_IncomeTaxReconciliationValuationAllowance
Income Tax Expense      
v2.4.1.9
Income Taxes (Details 2) (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Current Tax Expense    
Danish Income Tax      
Total Current Tax Expense      
Deferred Income Tax Expense (Benefit)    
Excess of Tax over Book Depreciation Fixed Assets      
Excess of Tax over Book Depreciation Patents      
Net Operating Loss Carry forwards (179,661)pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards (100,000)pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards
Change in the Valuation allowance 179,661pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount 100,000pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount
Total Deferred Tax Expense      
v2.4.1.9
Income Taxes (Details Textual) (USD $)
3 Months Ended
Mar. 31, 2015
Income Taxes (Textual)  
Net operating loss carryforwards expiration period Through 2034
Danish Tax [Member]  
Income Taxes (Textual)  
Net operating loss carry forwards 2,416,813us-gaap_OperatingLossCarryforwards
/ us-gaap_IncomeTaxAuthorityAxis
= pmhs_DanishTaxMember
U.S. Federal Tax [Member]  
Income Taxes (Textual)  
Net operating loss carry forwards 179,661us-gaap_OperatingLossCarryforwards
/ us-gaap_IncomeTaxAuthorityAxis
= pmhs_U.S.FederalTaxMember